This 42-year-old man had used a total of 4·5 g of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) over a 4-day period. This video shows footage after his initial admission to hospital in an untreated state (segment 1), and then following treatment with levodopa/carbidopa (segments 2 and 3).
Read the full Correspondence and video description in the supplementary material at The Lancet Neurology: www.thelancet.com/journals/lan...
Published: March 13, 2018.
13 мар 2018
